Lisata Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: LSTA · Form: 10-Q · Filed: May 9, 2024 · CIK: 320017
Sentiment: neutral
Topics: 10-Q, Lisata Therapeutics, Financial Report, Quarterly Filing, Pharmaceuticals
TL;DR
<b>Lisata Therapeutics, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial information and company history.</b>
AI Summary
LISATA THERAPEUTICS, INC. (LSTA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lisata Therapeutics, Inc. filed a 10-Q report on May 9, 2024, for the period ending March 31, 2024. The company was formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc. The filing includes financial data for the quarters ending March 31, 2024, and March 31, 2023. The company's principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920. The SIC code for the company is Pharmaceutical Preparations [2834].
Why It Matters
For investors and stakeholders tracking LISATA THERAPEUTICS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance and operational updates for Lisata Therapeutics, Inc. as of Q1 2024. Understanding the company's historical name changes (Caladrius Biosciences, Inc., NeoStem, Inc.) is crucial for tracking its evolution and past financial performance.
Risk Assessment
Risk Level: low — LISATA THERAPEUTICS, INC. shows low risk based on this filing. The filing is a standard 10-Q, indicating routine financial reporting rather than a significant event, thus posing low immediate risk.
Analyst Insight
Monitor future 10-Q filings for detailed financial performance and any strategic shifts announced by Lisata Therapeutics.
Key Numbers
- 2024-03-31 — Reporting Period End Date (Conformed period of report)
- 2024-05-09 — Filing Date (Filed as of date)
- 2023-03-31 — Prior Year Period End Date (Comparison period for financial data)
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Filer name
- 2024-03-31 (date) — Conformed period of report
- 2024-05-09 (date) — Filed as of date
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- NeoStem, Inc. (company) — Former company name
- 2834 (industry) — Standard Industrial Classification
- 110 Allen Road (address) — Business address street 1
- Basking Ridge (location) — Business address city
FAQ
When did LISATA THERAPEUTICS, INC. file this 10-Q?
LISATA THERAPEUTICS, INC. filed this Quarterly Report (10-Q) with the SEC on May 9, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by LISATA THERAPEUTICS, INC. (LSTA).
Where can I read the original 10-Q filing from LISATA THERAPEUTICS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LISATA THERAPEUTICS, INC..
What are the key takeaways from LISATA THERAPEUTICS, INC.'s 10-Q?
LISATA THERAPEUTICS, INC. filed this 10-Q on May 9, 2024. Key takeaways: Lisata Therapeutics, Inc. filed a 10-Q report on May 9, 2024, for the period ending March 31, 2024.. The company was formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc.. The filing includes financial data for the quarters ending March 31, 2024, and March 31, 2023..
Is LISATA THERAPEUTICS, INC. a risky investment based on this filing?
Based on this 10-Q, LISATA THERAPEUTICS, INC. presents a relatively low-risk profile. The filing is a standard 10-Q, indicating routine financial reporting rather than a significant event, thus posing low immediate risk.
What should investors do after reading LISATA THERAPEUTICS, INC.'s 10-Q?
Monitor future 10-Q filings for detailed financial performance and any strategic shifts announced by Lisata Therapeutics. The overall sentiment from this filing is neutral.
Key Dates
- 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
- 2024-05-09: Filing Date — Date the 10-Q report was officially filed with the SEC.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides investors with a comprehensive update on the company's financial performance and operations during the quarter.)
- SIC Code
- Standard Industrial Classification code used to identify industries. (Helps categorize Lisata Therapeutics within the pharmaceutical preparations sector.)
Filing Stats: 4,525 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2024-05-09 16:13:47
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
Filing Documents
- lsta-20240331.htm (10-Q) — 755KB
- lsta-ex311_20240331.htm (EX-31.1) — 9KB
- lsta-ex312_20240331.htm (EX-31.2) — 9KB
- lsta-ex321_20240331.htm (EX-32.1) — 7KB
- lsta-ex322_20240331.htm (EX-32.2) — 7KB
- lsta-20240331_g1.jpg (GRAPHIC) — 138KB
- lsta-20240331_g2.jpg (GRAPHIC) — 112KB
- 0000320017-24-000031.txt ( ) — 6151KB
- lsta-20240331.xsd (EX-101.SCH) — 46KB
- lsta-20240331_cal.xml (EX-101.CAL) — 57KB
- lsta-20240331_def.xml (EX-101.DEF) — 170KB
- lsta-20240331_lab.xml (EX-101.LAB) — 603KB
- lsta-20240331_pre.xml (EX-101.PRE) — 406KB
- lsta-20240331_htm.xml (XML) — 676KB
- FINANCIAL INFORMATION
PART I- FINANCIAL INFORMATION Page No. Item 1.
Financial Statements
Financial Statements: 5 Consolidated Balance Sheets at March 31 , 202 4 (unaudited) and December 31, 2 023 5 Consolidated Statements of Operations for the three months ended March 31, 202 4 and 202 3 (unaudited) 6 Consolidated Statements of Comprehensive Loss for the three months ended March 31, 202 4 and 202 3 (unaudited) 7 Consolidated Statements of Equity for the three months ended March 31, 202 4 and 202 3 (unaudited) 8 Consolidated Statements of Cash Flows for the three months ended March 31 , 202 4 and 202 3 (unaudited) 9 Notes to Unaudited Consolidated Financial Statements 10 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.
Controls and Procedures
Controls and Procedures 30
- OTHER INFORMATION
PART II- OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 32 Item 1A.
Risk Factors
Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 32
Signatures
Signatures 33 4 Index
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
FINANCIAL STATEMENTS
ITEM 1. FINANCIAL STATEMENTS LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share data) March 31, 2024 December 31, 2023 ASSETS (Unaudited) Cash and cash equivalents $ 21,805 $ 22,593 Marketable securities 21,544 27,942 Prepaid and other current assets 4,210 3,389 Total current assets 47,559 53,924 Property and equipment, net 146 175 Acquired license - intangible, net 245 263 Other assets 290 332 Total assets $ 48,240 $ 54,694 LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Liabilities Accounts payable $ 1,263 $ 2,421 Accrued liabilities 4,070 4,169 Total current liabilities 5,333 6,590 Other long-term liabilities 164 210 Total liabilities 5,497 6,800 Commitments and Contingencies (Note 13) Stockholders' Equity Common stock, $ 0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively 8 8 Additional paid-in capital 577,283 576,971 Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023 ( 708 ) ( 708 ) Accumulated deficit ( 533,482 ) ( 528,081 ) Accumulated other comprehensive loss ( 104 ) ( 42 ) Total Lisata Therapeutics, Inc. stockholders' equity 42,997 48,148 Non-controlling interests ( 254 ) ( 254 ) Total equity 42,743 47,894 Total liabilities, non-controlling interests and stockholders' equity $ 48,240 $ 54,694 See accompanying notes to consolidated financial statements. 5 Index LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2024 2023 Operating Expenses: Research and development $ 3,241 $ 3,179 General and administrative 3,360 3,665 Total operating expenses 6,601 6,844 Operating loss ( 6,601 ) ( 6,844 ) Other income (expense):